Print

Markets live transcript 9 Apr 2009

Markets live chat transcript for the chat ending at 12:07 on 9 Apr 2009. Participants in this chat were: Paul Murphy, FT (PM) Bryce Elder (BE) Neil Hume, FT (NH)

PM:
Hi there
PM:
Welcome to Markets Live
PM:
Maundy Thursday edition
PM:
Of Alphaville’s daily market chat.
BE:
Ooh, we going all religious for the day?
PM:
Get your feet washed at church.
BE:
???
BE:
Does the fact that we are seeking ML inspiration in the Lord have something to do with the lack of market features this morning?
PM:
Sure does.
BE:
Easter is upon us
BE:
So we might slope off earlier today.
PM:
I’m off for a week and ive got a TON of stuff to sort out.
PM:
Like my expenses.
BE:
PM:
Emails.
PM:
Apologies.
PM:
Send out fabulous Nomura prizes – which I still haven’t done.
PM:
All that sort of pre-holiday stuff.
PM:
Missing Alida
BE:
You going away?
PM:
New York – half work, half play.
NH:
Hi guys. sorry to intrude on your chat. just sent the Citrix password over
and a very good cazenove note on Diageo and Brown &Foreman
they see a bid as unlikely but say B&F could merger with Barcardi.
anway i think there is deffo something going on at B&F. and am on the case
BE:
Nice
BE:
Bit cold there at the moment, apparently.
PM:
So i hear
11:07AM
PM:
hi Neil — thanks for calling in
PM:
Bryce — shall we go straight to Diageo and B&F?
BE:
Sure
BE:
I have my own thoughts, of course, which Neil can agree with or contradict as he feels fit …
NH:
no probs. this is about the only story I am hearing at the moment. B&F and its advisers are said to be working round the clock on whatever this deal is
BE:
Had plenty of calls on it today
BE:
Think I mentioned here yesterday that the jungle drums had started beating about acquisitions.
BE:
And moved it forward a bit in the paper this morning
BE:
With the speculation Neil mentions above that Brown-Forman might be willing to talk deals
PM:
Interesting. Isn’t Brown-Forman family owned though?
BE:
Yup. There’s a complex A and B share structure that blocks anything hostile.
BE:
So we’d be talking friendly. And, given the overlap, brand disposals look much more likely than a full acquisition.
PM:
What does Brown-Forman own?
BE:
Jack Daniels and Southern Comfort are the biggies, obviously.
BE:
Which is where Diageo’s interest would lie, you’d have to assume.
BE:
There’s also a fair few wine brands …
BE:
Most of which I’m not too familiar with
NH:
oh, we can safely say DGE are interested
BE:
Jekel
Virgin Vines
Little Black Dress
Korbel California Champagnes
PM:
Discovered my eldest kid is a Southern Comfort drinker. Not sure i approve. Awful stuff
PM:
Anyway, can you have a California champagne?
PM:
Don’t the French tend to get upset about that kind of thing?
BE:
Note it’s “Champagne”. I suspect that capital letter is there for good reason.
PM:
Monkey as well
NH:
that should have been not interested – re Diageo.
NH:
goona leave u two to it now
BE:
Yup – we’re pretty sure Diageo is not talking them at the moment.
BE:
And it goes without saying that there would be plenty of hurdles to clear.
PM:
Anti-trust??
BE:
Quite. It’s going to be a challenge to get any kind of merger past the regulator.
PM:
Neil has sent over the Caz note
PM:
Cheers neil
PM:
I will share
PM:
Summary
The FT market section reports today that there was “talk of sector consolidation” within the beverages sector yesterday.

According to the FT “One theory in circulation was that Diageo might put together a friendly deal with Brown-Forman, the maker of Jack Daniels and Southern Comfort. The US group’s controlling shareholders [the Brown family] have been rumoured to be open to a sale or disposal, with Bacardi also linked with an interest. However, Diageo and Brown-Forman are not thought to be in talks.”

We see this as unlikely for two reasons. First, Brown-Forman (BF) has a longstanding commitment to independence, supported by the dominant influence of the Brown family. Second, BF has a close relationship with Bacardi, which involves joint distribution in many markets. Were BF to seek a deal we see Bacardi as the more obvious partner, for this reason and because of the more similar size of the two companies. A deal between BF and Bacardi could be something akin to a merger, whereas a deal with Diageo would be a straight takeover of BF.

PM:
Regulatory issues
We believe that a deal between Diageo and BF would be subject to US anti-trust investigation. Such inquiries are not as clear cut in spirits as in beer as they are usually based more on category dominance than overall market share (where the acquisition of BF would take DGE from c.26% to c.33% share in the US).

The decision can therefore come down to how categories are defined. For example, we would argue that Diageo has no significant presence in the premium American whisky category, where BF’s Jack Daniels is the leading brand in the US. However, if this category was defined more widely as all American whiskey regardless of price then Diageo’s ownership of the Seagram’s 7 Crown brand could be an issue (these are the no.1 and no.3 American whiskies in the US market). Similarly, if the whisk(e)y category was defined more widely regardless of national origin, then Diageo ownership of the Crown Royal Canadian Whisky brand could be problematic. Jack Daniels and Crown Royal are the two leading North American whiskies in the US market and sell at a similar price point (Jack Daniels $20.30, Crown-Royal $22.90).

PM:
Perhaps the most contentious regulatory issue would arise from Diageo’s ownership of the Baileys brand and BF’s ownership of the Southern Comfort brand, with both being whisk(e)y-based liqueurs. The vodka category is probably sufficiently fragmented for BF’s ownership of the Finlandia brand not to be an issue despite Diageo’s ownership of the Smirnoff brand.

Although it is too early to start wondering about the impact on Diageo’s EPS and ROIC given that we have no idea on price (even if the deal went ahead) we would make the following general point. Deals in the spirits industry can go ahead at substantial premiums whilst still creating value for the acquirer given the synergies available. In this case Diageo could acquire BF’s brands and incur very limited additional cost in distributing them, thus making a substantial saving. Given this point, and the strategic merits for Diageo of acquiring another category-leading brand, we would be supportive of a deal as long as the price was not stratospheric.

The FT also reported that “Another suggestion [yesterday] was that Diageo might look at buying a brewer, which would be less likely to trigger competition concerns.” This is a longstanding theory put forward by some of our competitors. We give it no credence as it would almost certainly dilute Diageo’s returns, growth and focus on the premium spirits category, and hence be inconsistent with the company’s strategy.

BE:
Yup … all sensible stuff.
BE:
Should also mention trading’s not too happy at the moment
BE:
Weak results from Constellation Brands yesterday, the world’s largest wine maker
BE:
Along with the Pernod profit warning, of couse.
BE:
Seems like there’s loads of excess inventory in the system
BE:
Actually, on Pernod …
BE:
Some analysts reckon their sale of Wild Turkey yesterday would seem to make them a better fit for Brown-Forman.
BE:
No sourmash overlap, basically.
BE:
And, as Caz notes, there are these rumours about Bacardi getting involved
BE:
Talk that it’s struggling in the vodka as people trade down from Grey Goose
BE:
So Brown-Forman’s Finlandia brand might provide a solution of sorts
BE:
Anyway, please note this is all industry-level speculation rather than proper raw.
RAW is market chatter – information that has not been formally tested through traditional journalistic channels (PRs etc). The story might be complete rubbish, but if we believe there is some substance to it we will say so. Either way, Reader Beware.
PM:
Thanks for all that
PM:
interesting
PM:
As is the link supplied by The Hoof below
PM:
Just tack a snap..
PM:
At that time the words ‘Champagne’, ‘Burgundy’, ‘Port’ and ‘Sherry’ were no longer allowed to be used in America. Just this past month the EU added another restriction to American winemakers’ verbage. Wines bearing these words on their labels will no longer be sold in Europe:

‘chateau’, ‘classic’, ‘clos’, ‘cream’, ‘crusted/crusting’, ‘fine’, ‘late bottled vintage’, ‘noble’, ‘ruby’, ‘superior’, ‘sur lie’, ‘tawny’, ‘vintage’ or ‘vintage character.’

Bureaucracy at its finest. I certainly understand protecting rights to regions but not simple words with more than a location’s name at heart.

PM:
Quite ridiculous
BE:
It’s political correctness gone etc.
11:17AM
PM:
it is rate decision day at the Bank of England today.
BE:
No change
BE:
We assume.
PM:
In fact it is not really worth having a competition.
PM:
BE:
Maybe we could just ask the crowd if anyone thinks we will get some sort of move?
PM:
Could do.
PM:
So, friends below, will there be some sort of statement on QE etc??
BE:
Friends eh?
PM:
Yeah, most of them.
PM:
I think
PM:
Hope
PM:
Pray
BE:
Oh dear, we’re back to God
BE:
Theology Live
BE:
Got any research on UK rates?
PM:
No –not immediately. Think it is such a foregone conclusion that no one is bothering much.
PM:
Actually do have a piece from Jamie Dannhauser at Lombard St Research
PM:
Saying manufacturing screwed – but service sector bottoming out.
PM:
He’s actually saying sterling is undervalued against the euro
PM:
SUMMARY: The pace of contraction in UK industrial production slowed in
February; but the drop in output over the whole of Q1 is set to be larger than in Q4
last year. However, recent survey evidence suggests that activity in the service sector
may be close to bottoming out.
PM:
Given the long history of many of the surveys covering the manufacturing sector and the
timely data published by the ONS, economic coverage tends to be biased in favour of the
goods-producing industries. But in the UK, only 20% of the value-added of the market
economy (excludes public sector activity) comes from the industrial sectors. With reliable, accurate and up-to-date figures hard to come by for service-sector activity, there is therefore a danger that analysts are slow to capture turning points in the overall economy. These problems are likely to be particularly acute at the moment since much of the collapse in economic activity world-wide has been related to a sudden drop in trade
volumes, particularly within the motor vehicle trade, and massive inventory liquidation in
the manufacturing sector.

Industrial output in the UK has dropped 13% from its peak early last year and, after the 1% decline in February, is set to be down roughly 5% in Q1 from Q4 – alone reducing the
level of GDP by a little over 1%. These figures are consistent with recent evidence from
the host of business surveys covering the sector (e.g. CBI, BCC, PMI), which all report
still shrinking order books and elevated inventory levels. The largest drop in car sales since the mid-70s recession has been particularly problematic for UK industrial firms, not least the large network of domestic parts suppliers.

PM:
However, for all the doom emanating from the manufacturing sector, there is better news
from private sector service-based industries. The widely-tracked monthly PMI services
index has risen in each of the last four months and is now at its highest point since last
September, although it remains consistent with falling output. Moreover, both the level and trend of the index show the UK to be better placed than most of the other developed world economies (see chart above). The quarterly survey from the British Chambers of
Commerce, which is based on a much larger sample of firms, offers up a similar picture.
Although new orders and current activity appear to be falling, the rate of decline has
slowed and is no worse than that seen in the early 1990s recession.

The case in favour of a return to growth during the second half of the year remains in
place. Large-scale asset purchases by the central bank appear to be having a meaningful
impact on monetary conditions and corporate liquidity. Car sales, the collapse of which has been a major component of the manufacturing malaise, appear to have flattened off at a monthly rate of 140,000 (LSR seasonal adjustment). Meanwhile, the inventory overhang appears limited in the UK, with massive liquidation at the end of last year leaving stock levels in line with their long-term trend (i.e. a better position than normally would be the case at this point in the cycle). However, in Q1 the scale of the output decline is set to be larger than we had forecast in our January Quarterly Economic Forecast, most likely ending up in the 1-1½% range rather than the ½-1% range previously assumed (markedly worse outturns for manufacturing activity outweighing better than expected news from the service sector).

BE:
Phew. That’s a lot of reading.
PM:
sorry
PM:
Actually, should put the trade figures up.
BE:
Hmm – these are being read in different ways.
BE:
The release is here
BE:
The key par most people are focusing on is this
BE:
The deficit with non-EU countries narrowed to £4.0 billion compared with the deficit of £5.6 billion in January. Exports rose by £1.0 billion while imports fell by £0.7 billion. There were rises in exports of chemicals, intermediate goods, and consumer goods other than cars. There were falls in imports of oil, fuels other than oil, and aircraft.
BE:
Weak pound helping exporters.
BE:
That might even be another green shoot, Murph.
PM:
Dontcha just want to trample all over this green shoot nonsense.?
PM:
Kick dirt all over the flower bed?
BE:
Saw you put some stuff up from peter Oppenheimer earlier.
PM:
Ah, yes, PO at GS.
PM:
They are very cautiously bullish.
PM:
Think we saw the bottom in February, stock wise. So making selective purchases…
PM:
Here’s his summary
PM:
We maintained a defensive sector portfolio for 18 months, but have recently begun to moderate this stance. Recent data makes us more confident the worst in the economic cycle is past, and we further move towards cyclicals from defensives. But deleveraging is likely to drive a series of ‘mini-cycles’, in our view, and we want to remain nimble as they ebb and flow.

The pace of economic deterioration has slowed
Our economists believe that we are past the low point in the economic cycle, although we are far from
expansionary territory. This is one of the signposts we were waiting for before getting more positive on the market and cyclicals. But it does not mean it is the start of a new bull market – it is dangerous to view the current cycle as ‘normal’ given the overlay of the ongoing credit crunch and balance sheet deleveraging. Our strategy is to trade the cycles as they emerge, but be nimble as we may need to make more frequent sector changes than typically following a trough.

PM:
Nearing the trough of the cycle
Since last December, we have reduced some of our defensive bias and selectively increased cyclicals. Given the recent data, we move further in that direction; upgrading Industrials to Overweight and Tech and Travel & Leisure to Neutral and downgrading Health Care to Neutral and Food & Beverage to Underweight. We also upgrade Utilities to Neutral as it has underperformed and could benefit from further energy price strength.
PM:

Earnings estimates need to fall, but does anyone care?
Consensus earnings expectations remain too high for this year, in our view, and we expect large downward revisions over the next few months, with the 1Q reporting season a catalyst. But growth and value metrics are likely to be less a driver of relative performance at this stage of the cycle.

BE:
Ta for that.
11:22AM
PM:
Wider market
BE:
Flat.
BE:
Chopping around breakeven all morning
BE:
FTSE currently up 11 at 3636
PM:
Hmm — all a bit pre-Easter
BE:
Yup
BE:
Very quiet
BE:
Volumes have been sliding all week
11:24AM
PM:
Now, we being put on the spot over Pearson below
Pearson plc is the parent company of the Financial Times, publisher of FT Alphaville.
PM:
How are the various media stocks doing this morning?
BE:
Er, pretty mixed it think.
BE:
Why do you ask?
PM:
Well, I believe there was a very thoughtful note out of Bernstein on the sector this morning.
BE:
Thoughtfully positive on Pearson, you mean.
PM:
No no – don’t be so cynical. Wouldn’t dream of trying to manipulate the price of our publisher.
BE:
Well if you were it would be without success. Stock is off 15p at 669p.
PM:
Well, in any case we should share what Claudio Aspesi at Bernstein is saying.
PM:
Highlights
The recent rally in cyclical stocks is leading media investors to wonder whether the time has come to start buying into the more cyclical stocks (such as FTA TV). Since the market low on 9th March 2009, the FTA TV stocks in our coverage have gained 28% on average in absolute terms (and 13% relative to the MSCI Europe), outperforming the more defensive Professional Publishers by 24% and leading investors to ask whether they should start buying into the more cyclical stocks.

Cyclical stocks such as FTA TV highly correlate with sales (advertising revenues) and earnings revisions. We think that we are far from seeing conditions leading to positive earnings revisions for the advertising driven stocks. Given the continued negative earnings revisions of the TV stocks in our coverage, further deterioration in macro economic forecasts, the fact that, in a recession, the advertising market typically lags any economic upturn by one to two years, and our analysis of FTA share price performance in the early 90s recession, we think that it is still to early to buy into TV stocks. The experience of earlier recessions in which advertising recovery lags the recovery of the economy at large suggests that – even when the economy finally starts to show better performance – there is a risk of a
short rally followed by further disappointment as the expected advertising revenues and earnings do not come through concomitantly.

PM:
If the recession lasts much longer, we fear that structural issues could negatively affect the recovery of cyclical stocks even more. In addition to the cyclical issues, consumer media stocks also face the negative impact of structural transition from oligopolies and monopolies to more competitive and fragmented industry structures. Even before the onset of the recession, the performance of European consumer media stocks was deteriorating: average operating margins for FTA broadcasters declined by200bp between 2005 and 2007 in a benign economic environment. Consequently, we think that a prolonged recession may further exacerbate these trends by leading to content spending cuts that could further affect market share and future competitiveness. As a result, the likely anticipated advertising revenues and earnings may not materialize as much as expected when the economy recovers.

We still prefer defensive/late cyclical stocks with lower exposure to the economy. For investors looking for some exposure to the economic cycle, we still recommend Professional Publishing stocks, since they show less downside if the economy continues to deteriorate and are not affected by negative structural issues. In addition the Professional Publishers do have some exposure to more cyclical business (Reed Elsevier: Exhibitions and RBI, Pearson: FT newspaper, Wolters Kluwer: transactional segment of Corporate and Financial Services division) for which estimates of a severe downturn are already for the most part factored into estimates. Should the economy recover earlier than anticipated, these businesses could still surprise on the upside, with the result that the stocks should not be left as far behind as some investors envisage.

PM:
_ Among the Professional Publishers we most favour Reed Elsevier (target prices £6.25/€11.00).
The company is attractive valued, trading at a 3%/-4% and 2%/-5% premia (PLC/NV) to the MSCI Europe Index P/E in 2009 and 2010 respectively on SCB estimates which represents historic lows relative to the market. Reed Elsevier also has the highest earnings growth of the three Professional Publishers in our coverage with a projected 15.7% 2009-12E EPS CAGR.

_ Within the TV segment, we rate BSkyB Outperform (target price £5.50). We continue to believe that Pay TV will remain resilient even in the current economic environment and that the company will in fact emerge as a beneficiary due to the weakening of its FTA competitors in the UK TV market.

PM:
We have adjusted our target prices and forecasts to reflect changes in FX and the market multiple.
We have adjusted our estimates and reviewed our target prices for the Professional Publishers (Reed Elsevier, Pearson and Wolters Kluwer) and Vivendi to account for the changes in FX, the market multiple, and following the release of Vivendi’s annual report, we have updated our numbers for the company to account for the 2008 results (we do not view the disclosure on results day sufficient to fully adjust our forecasts). The changes to our forecasts for the Professional Publishers are relatively minor (between 1.8% and -3.4% for 2009 and -2.4% and -3.9% for 2010). Of the Professional Publishers we have only changed our Pearson target price, which increases from £7.00 to £7.50 and maintain our Outperform rating on the stock. Our 2009 Vivendi adjusted EPS estimate declines 12.9% from €2.78 to €2.42 and our 2010 forecast declines by 11.8% from €2.79 to €2.46. We have lowered our target price
for the company from €23.00 to €22.00. Our TV earnings estimates and forecasts are unchanged.

BE:
So you printed all that just to get in mention of the fact that Bernstein have upgraded Pearson from 7 quid to £7.50?
PM:
PM:
Well, there’s another 36 pages of it – so count yourself lucky.
BE:
Hm.
BE:
Let’s move on.
11:26AM
PM:
Miners look to be rallying a bit
PM:
I assume that’s after the Vedanta Q4?
BE:
Well, it’s as good a reason for the bounce as any.
BE:
Production numbers look pretty much in line
BE:
Bit of comment on the stock from Michael Rawlinson at Liberum
BE:
At £7.73/shr Vedanta may seem expensive on consensus 23x PE, 6.2x EV/EBITDA; but we would highlight that the company is exposed to commodities that have been hit the hardest and see asymmetrical upside risk to current levels, well positioned for a recovery with cash and best in sector near-term growth plans. The most compeling metric to illustrate just how cheap Vedanta is its price to sales ratio of 0.5x vs 2.7x for BHPB, 1.25x for Rio Tinto and 1.0x for Xstrata. We also note that Vedanta is now same price as its stakes in Sesa Goa plus Sterlite, meaning investors get Zambian copper, the aluminium business and some cash for free. With the copper price now close to $2/lb the cash burn in KCM is tending to zero so these assets are clearly worth more than zero.
BE:
23 times PE does look heroic.
BE:
Actually, I’m a bit surprised to see the miners up today.
PM:
Why’s that?
BE:
Well, for one we’ve had a profit warning of from Posco
BE:
of sorts
BE:
Dow Jones reported that Chief Financial Officer Lee Dong Hee said the company expects quarterly earnings to miss market expectations.
BE:
The numbers are due tomorrow.
PM:
That’s an innovative way to warn.
BE:
Isn’t it just?
BE:
And bear in mind this comes at a time when we’re waiting for the miners to fix their 2009 iron ore price with the Asian steelmakers
BE:
news on which is becoming like Waiting For Godot.
BE:
Talk of a deadlock. Spot market sliding.
PM:
Can we put up a few prices?
RIO TINTO (RIO:LSE): Last: 2,280, up 37 (+1.65%), High: 2,300, Low: 2,204, Volume: 2.49m
Xstrata (XTA:LSE): Last: 559.50, up 35.5 (+6.77%), High: 560.50, Low: 526.50, Volume: 6.05m
BHP Billiton (BLT:LSE): Last: 1,384, up 27 (+1.99%), High: 1,409, Low: 1,362, Volume: 4.06m
PM:
What about Anglo American?
BE:
Same as the rest really.
Anglo American (AAL:LSE): Last: 1,339, up 32 (+2.45%), High: 1,365, Low: 1,311, Volume: 2.09m
PM:
Did you read that story about De Beers in today’s paper?
PM:
De Beers, the world’s biggest diamond miner, is planning for its turnover to halve this year, it emerged on Wednesday, in the latest sign of how the once-mighty group is struggling to cope with a downturn in an industry it no longer controls.

With diamond prices tumbling by at least 30 per cent over the past year, De Beers has cut production at its mines by 40 per cent year-on-year and mothballed its flagship mines in Botswana.

BE:
Yeah. Interesting piece. Follows on from something we wrote in the market report a few days ago.
BE:
Which was following on from a poppy bit of research from BarCap.
BE:
Anglo owns 45% of De Beers, of course, although it’s debatable whether investors are pinning much value to that stake
BE:
Anyway, Michael Rawlinson (again) reckons De Beers is in even deeper than our report indicated.
BE:
The lead story in today’s FT is that Anglo American’s 45% associate De Beers is bracing for turnover to halve. We expect De Beers’ turnover will undershoot even a halving of turnover target and expect sales closer to $2-2.5bn, with negligible EBITDA. We expect De Beers to finish 2009 with net debt of $4.0-4.5bn, which will possibly be more than the value of its equity. Worryingly $1.5bn is due for repayment in 2010 and it is not clear how this will be refinanced. Commercial lending is unlikely to be available and it is not clear whether the key shareholders should even fund the shortfall if the asset has negative net value. If they do fund, it is almost certain they will put in debt as opposed to equity so as to assure they are on the list of creditors should the equity get wiped out. De Beers is now a neglible influence on the Anglo valuation but it clearly has the potential to be a further drain on cash flows in 2010 if Anglo are to support it. We feel Anglo is still the least preferred of the big four – it has the most expensive PER. Although it has a similar EV/sales as XTA it has more structural problems (Amplats losses, De Beers, balance sheet structure and board/management succession issues).
BE:
Apologies for the delay to your service – the FT email’s gone on the blink
PM:
Mines broken — for now
PM:
But can live without it for a bit
11:34AM
PM:
Solvay
PM:
Story on reuters this morning — bascially confirming Miles and Neil’s story from last week
BE:
Yup
PM:
Pharma business up for sale
PM:
Adds however that an auction for the dvision is likely to be held
PM:
Funny the way the involved parties have tried to avoid coming clean on this
PM:
Well, no tthat funny at all
BE:
typical behaviour
PM:
Anyway, Bryce seen any research on this as yet??
BE:
Well, here’s Morgan Stanley on the matter
BE:
Upgrading to Equal-weight. Following Solvay’s announcement it is “proceeding with … various options for its Pharmaceutical activities”, we believe the investment case shifts from underlying fundamentals to the binary outcome of M&A. As a result, we believe there has been a fundamental shift in the risk/reward profile of the shares and now see a more reasonable balance between downside risks (no deal for Pharma, Chemicals and Plastics deteriorating further) and upside risks
(Pharma sold and equity market ascribing mid-ccle multiple to remaining cyclical activities).
BE:
Bull case potential upside of 33%, bear case downside of 36%. Our new bull case value of €77 per share assumes that see the Pharma division is sold for c9x 2009 EV/EBITDA (in line with recent pharma deal multiples). In addition, the remaining Chemicals &
Plastics divisions attract a 6x EV/EBITDA multiple on depressed 2009e forecasts. Our bear case value remains €37 per share and assumes no Pharma sale, with a further deterioration in profitability within Chemicals and Plastics
BE:
Current share price discounting c50% probability of Pharma division sale. Marking to market the value of Chemicals & Plastics using peer multiples, we back out that the Pharma division is currently valued at 7-7.5x 2009 EV/EBITDA. This represents a premium to the Pharma sector average of c15%, but remains c17% below the 9x EV/EBITDA M&A multiples seen in recent
pharma deals.
BE:
Underlying valuation still looks rich to us. Solvay is trading on a 2009 P/E of 12.4x, on our estimates, a c30% premium to Bayer’s c9.5x multiple.

PM:
ta
11:38AM
BE:
Vixen …
BE:
If we had anything new on Chloride we’d tell you
BE:
Emerson had a profit warning earlier this week of course
PM:
Er, well i’ve got my fingers on something beginning with “Z”…
BE:
That RAW caveat above is not just bumperplate.
11:40AM
BE:
Ok – this delay to your service is due to Paul getting the zapper out
BE:
All done?
PM:
Sorry — no — was just checking a few people’s comment history
PM:
No need to use the zapper
BE:
Self regulating. The system works.
PM:
Just on Chloride come way down from its highs
PM:
trading at 152p currently — up 5% on the day
PM:
e nothing NOTHING new
PM:
If you are worried about the stock — sell it and stop worrying
BE:
(And thanks for the bumperplate/boilerplate corrections below.)
11:44AM
PM:
What else Bryce??
BE:
Bit of best practice, while we’re here
BE:
Agriterra.
PM:
Who?
BE:
The former White Nile.
PM:
PM:
Phil Edmonds.
BE:
Yup. The former England spinner’s Sudanese oil explorer turned African agripunt.
BE:
There have been rumours going round about a possible fundraising.
NH:
Hi Guy, just logged back in. Have we red carded Vixen yet, or can I do it.
BE:
Which we mentioned in the paper overnight.
BE:
However, it appears to be malicious gossip
BE:
No truth in the tale.
BE:
Quoth a spokesman …
BE:
absolutely no truth in today’s report that Agriterra was raising money
BE:
as it has adequate cash in the bank and revenue from existing operations to fulfil its expansion strategy in Mozambique
BE:
This is focussed on replicating DECA, its successful cash generative and profitable maize buying and processing operation centred on Chimioi in central Mozambique, in the northern province of Tete through its Compagri subsidiary. The Company, which sells 15% of its production to the World Food programme, is also expanding into cattle ranching, which is again being funded out of internal cash flow.
BE:
So I hope that clears things up sufficiently.
PM:
cheers
BE:
(cityunslicker – AV doesn’t “tip”)
11:48AM
BE:
While we wait for the rates decision …
BE:
Can bring you some more Solvay research
BE:
Which I know is a hot topic for several readers
PM:
While you are getting that i will put up some LIBOR rates
PM:
The London interbank offered rate, or Libor, for three-month loans in dollars declined for a 10th day, according to the British Bankers’ Association.
The rate banks say they charge each other dropped one basis
point to 1.13 percent today, the lowest level since Jan. 21, the BBA said. The Libor-OIS spread, a gauge of bank reluctance to lend, narrowed one basis point to 92 basis points
PM:
09/04/2009 04:27:53 AX JGBs drop on prospects of more supply, upbeat data
PM:
09/04/2009 11:39:06 DI *DJ 3-Month USD Libor Falls To 1.13125%, Vs 1.13875% Weds
PM:
09/04/2009 11:38:50 DI *DJ 3-Month Euro Libor Falls To 1.42813%, Vs 1.4425% Weds
BE:
Ta.
PM:
09/04/2009 11:38:29 DI *DJ 3-Month Sterling Libor Falls To 1.56375%, Vs 1.57375% Weds
PM:
Solvay?
BE:
Sure. This from Oppenheim
BE:
The upgrade is a speculation on Solvay’s potential divestment of its
pharma business. The reasons for an M&A transaction with its pharma
business: 1) lack of critical size in pharma; 2) attractiveness of the
pharma pipeline and the capabilities to develop the pipeline are limited,
which provides future growth below the industry average. A divestment
or merger would provide increased profitability for the coming years; 3)
advisors hired to screen options might clearly favor a separation of the
pharma and chemicals businesses; and 4) current opportunities to sell
the existing pharma businesses are good as consolidation is proceeding
due to a lack of new projects in the industry, larger patent expiries, and
profitability of pharma companies are somewhat under pressure due to
various healthcare reforms.
BE:
Cash from any potential divestment could be used to cash out or reinvest
in other chemical businesses with low cyclical exposure to retain
a balanced portfolio.
• A couple of days ago Solvay indicated that it has all options under
review for its pharma business. In our view, a divestment, e.g. to Sanofi
or Abbott, or a merger with, e.g. UCB, are the most likely options. Other
interested parties cannot be ruled out (e.g. AstraZeneca).
• According to our SOTP valuation, a break-up value comes to €66, which
is our new FV. In the case of a divestment and under the assumption
with synergies, the value clearly increases beyond €80 (with €300m
synergies generated by the potential buyer, and half of that will be
distributed and paid to Solvay).
BE:
The downside is limited as first signs of an economic recovery occur
and the value without any M&A transaction is at €54, just some 6%
below the current value. The risk-reward ratio for an investment is
favorable.
• New rumors underlined our industrial rational, and mentioned a formal
two stage investment process to start just after Easter.
BE:
break-up value would result in €66 per share, assuming EV/EBIT
multiples of 10 for pharma (€5.7bn).
CONCLUSION
The need for a potential divestment or a merger of Solvay’s pharma
business is clearly there. Hedging for its remaining cyclical
Chemicals and Plastics business after a divestment could be
reached by a new investment in less cyclical chemical assets. We
recommend investing in the Solvay share as the risk-reward ratio is
favorable and downside is limited. Upgrade to Buy with an increased
fair value of €66.
BE:
And I think ING has an upgrade out as well
BE:
Actually, just the price target
BE:
Solvay confirmed that it is analysing various options for its pharma
activities, stating this included discussions with third parties but
without any further comments. Although we do not rule out a
potential deal, the quality of the Pharma business and the value we
attach to the remaining bulk plastics/chemicals lead us to believe
the 36% share price rise in 13 trading days has unlocked much of
the value already, not to mention our eyebrows.
BE:
Outcome unknown. Is the last real hybrid chemicals/pharma company left standing in
Europe on its knees? The Solvay family controls 30% of the company through the
vehicle Solvac, which implies it will need to give the go-ahead in order for any deal to
succeed, and above all we believe a stiff premium to relinquish control. The strength of
the long-term view is shown by downturns like these, so there needs to be a real
trigger to proceed with a sale of the pharmaceuticals business. These could include
the current M&A wave in pharma, the possible introduction of a capital gains tax in
Belgium and perhaps the need to monetise some assets. What will be done with the
cash? Assuming it is a family/Solvac decision and they have held on to the business
for this long, a fair chunk would probably be returned to shareholders (they could have
sold when the shares were close to €100). Perhaps current depressed prices for
assets in the chemical industry might tempt a bid for Arkema or Ineos, the two
businesses where there is the most overlap with the remaining units if Solvay were to
divest Pharma.
BE:
Not a best-in-class operation. Of course peer multiples for Pharma do not include a
take-out premium, but is there any? The Pharma division is a very low margin business
with an 18.9% REBIT margin. This is largely a reflection of the lack of scale, a portfolio
of drugs with small addressable markets and some generic products. Its largest
product, Tricor, will be replaced by Trilipix, but it will face generic competition by 2011.
Big Pharma stocks with very large patent cliffs in the next few years are trading on 5.5x
EBITDA. Moreover it has an R&D unit that has produced very little over the last few
years so we do not believe that it should trade on a higher multiple. If we add a 20%
premium to this we get to a valuation of €4.3bn or 1.4x sales. Of course Solvay could
also decide to divest non-core (ie, non Cardiometabolic and Neuroscience) activities,
partner these, merge or spin off Pharma but for the sake of simplicity we have valued
the whole division.
BE:
SOTP suggests value between €51-65 depending on assumptions. Low-end
assumptions value Pharma in line with our sector specialist’s view and the Chemicals
and Plastics in line with specialty chemicals peers and on 2009F forecasts. The high
end (€5bn) assumes Solvay Pharma should be valued higher than European mid-cap
Pharma (already prone to inflated multiples as of late) and the Plastics and Chemicals
divisions on our 2010F EBITDA times the 2010 consensus multiple for European
specialty chemicals. In the event, greed in the M&A context is hard to fathom but a
rerating of chemicals is still too early. Speculative BUY but a fundamental HOLD.
BE:
Hope that’s useful
11:55AM
BE:
Can have a quick look at Autonomy as well
BE:
Not much of a response to another one of those “we expect Q sales to beat expectations” announcements they tend to put out habitually
BE:
Up 23p at £1358 when I last checked.
BE:
Suspect investor views just are polarised and entrenched on this one
BE:
Either you think it’s a recession-proof killer ap with an ever broadening horizon of markets to plunder
BE:
Or you think it’s an acquisition machine with a questionable take on what qualifies as organic growth
BE:
And nothing the company says changes anyone’s mind
BE:
Here are a few views from both camps
BE:
Goldman on the bull side
BE:

Autonomy released a positive trading update today with 1Q2009 revenues
expected to be in the range of $128-130 mn, which is ahead of our
estimate and Bloomberg consensus of $126 mn. PF EPS is expected to be
significantly ahead of our estimate and consensus of $0.15.
BE:
Analysis
We believe the upside is on the core Autonomy business and implies
organic revenue growth at constant FX in the 22%-24% range. Excluding
the impact of super deals, we expect organic growth was likely nearer
11%-12%, in line with the 4Q2008 run rate. We believe the Interwoven
contribution for the 1Q2009 stub period was likely in line with our $7 mn
estimate. We estimate operating margins were likely 40%+, ahead of our
37.8% estimate, further demonstrating the operating leverage inherent in
the business. We believe the underlying momentum in the business is
likely stronger than 1Q2009 results suggest as we believe the company
may not have fully recognized recently announced large contracts,
providing the capacity for further estimate upgrades through the year.
BE:
Implications
While the preannouncement should not come as a surprise to the market
given the recent contract wins, we expect Autonomy’s shares to react
positively to this news as the underlying momentum in the business
remains strong despite the weak macro and software industry backdrop.
The strong underlying growth in 1Q is more impressive considering this is
a seasonally slower quarter in the year. The positive trading update
coupled with the recent large deal announcement with a global bank,
provides significant room for upwards revisions to our estimates and
consensus, which continue to take a prudent view to business growth. We
continue to believe unstructured data management remains decoupled
from broader IT spending and the macro uncertainty owing to secular and
regulatory factors. We reiterate our Conviction Buy on the stock. Our price
target is unchanged.
BE:
And Evolution on the bear side
BE:
Questions over core business raised
EVO TAKE – This update is, at first glance, very positive but in fact raises significant questions over the underlying growth of the core business. Combining this with the heavy cost-cutting evident in Q4, and the slowdown reported by other eDiscovery vendors (Guidance, EMC, FTI Consulting) suggests that risks to FY09E are higher than the market believes.
BE:
DETAILS – Autonomy has released an unscheduled trading update indicating revenues and EPS are significantly ahead of consensus. We expect the initial reaction to be positive, but we believe the performance from the core business to be disappointing as it raises significant questions over the achievability of FY09E forecasts. Revenue of $130m for the quarter, when adjusted for Interwoven inclusion (c$8m) and the impact of bank megadeals (c$18m v $1m in 1Q08A) imply core business performance was flat YoY. When considering hosted revenues (c45% of non-OEM licences on our estimate) should be growing, this implies that either OEM or core perpetual licences are in decline. Our unpublished 1Q estimates were for $144m revs, only implying a continuation of the underlying Q4 11% growth, and 18c (Autonomy say significantly ahead of 15c consensus, hence we think this looks right). Thus, we may downgrade our revenue estimates while keeping our EPS estimates intact for FY09E.
BE:
VALUATION AND RECOMMENDATION – Autonomy is an expensive stock at 18x cash-adjusted FY09E and 5.6x EV/Sales, albeit the former rating has come down through 2008. We think the company’s exposure to perpetual licence sales is material at c$250m FY09E, representing over 70% of EBIT, and so questions over core growth of licences are serious. The group’s core EBIT margin profile is fat at 50% Q408A and we think this is one reason why Interwoven was bought; to give management another cost base to slash to outperform during a period of potential top-line weakness.
PM:
Okay — thanks for all that
11:57AM
PM:
To fill the three minutes between now and rate time…
PM:
I hate to do this…
PM:
But here is some RAW
PM:
On a penny dreadful
BE:
Excellent
PM:
Nah — i do hate– the stock is sub-penny
PM:
spread as wide as…
PM:
DO NOT BUY THIS STOCK
PM:
REPEAT — DO NOT BUY THIS STOCK
BE:
PM:
Vatukoula Gold Mines
PM:
Okay
PM:
Vatukoula will likely get a takeover bid — either later today – or over the weekend
PM:
Its a dangerous situation
PM:
But it will get a bid
BE:
UK based mining and exploration company with gold projects in Fiji and Brazil and a exploratory diamond project in Sierra Leonne
PM:
As i understand it the bid is coming from a Canadian company called Canadian Zinc
PM:
Maybe, — subject to the usual caveats
PM:
And its a sub-penny dreadful
PM:
says it is something to do with a guy called Wally Berrukoff
BE:
Right – rates
BE:
The Bank of England’s Monetary Policy Committee today voted to maintain the official Bank Rate paid on commercial bank reserves at 0.5%. The Committee also voted to continue with the programme, announced on 5 March, of asset purchases totalling £75 billion financed by the issuance of central bank reserves.

The Committee noted that since its previous meeting a total of just over £26 billion of asset purchases had been made and that it would take a further two months to complete that programme.

The minutes of the meeting will be published at 9.30am on Wednesday 22 April.

PM:
Apparently he caused a stink at the Vatukla sharehodler meeting couple of weeks back — i think he will back the bid
PM:
So no change in rates
BE:
No statement
BE:
Continuing with the APP
BE:
Meh, basically.
PM:
Just to finish on this Vatukoula stuff — seems this shareholder rebellion brought in the offer (if it arrives — reader beware)
BE:
This tiddlertrage is much more interesting than the rates, frankly.
BE:
Even if it does come with a caveat emptor as big as the moon.
PM:
PM:
Alright — we are done
PM:
thank you Bryce
PM:
And thanks for all the funny comments below
BE:
Pleasure.
PM:
Im off for a week — but you will have Bryce and Neil here from Tuesday
PM:
At 11am
PM:
No ML tomorrow or Monday. Will be eating Easter eggs
PM:
AND — i can tell people that Tracy is preparing an Easter Egg Competition for Alphaville a little later today
PM:
So do come back to the homepage a little later
PM:
Probably mid afternoon
BE:
(Barman – don’t think the state of Arcandor is really a surprise to anyone at this point)
BE:
Ok – must go
PM:
And me — seeya
Print